Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and (90)Y-DOTA

Pretargeted radioimmunotherapy (PRIT) has been investigated as a multi-step approach to decrease relapse and toxicity for high-risk acute myeloid leukemia (AML). Relevant factors including endogenous biotin and immunogenicity, however, have limited the use of PRIT with an anti-CD45 antibody (Ab)-str...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Orozco, Johnnie J., Kenoyer, Aimee L., Lin, Yukang, O’Steen, Shyril, Guel, Rosario, Nartea, Margaret E., Hernandez, Alexandra H., Hylarides, Mark D., Fisher, Darrell R, Balkin, Ethan R., Hamlin, Donald K., Wilbur, D. Scott, Orcutt, Kelly D., Wittrup, K. Dane, Green, Damian J., Gopal, Ajay K., Till, Brian G., Sandmaier, Brenda, Press, Oliver W., Pagel, John M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7718432/
https://ncbi.nlm.nih.gov/pubmed/33082277
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-20-0306
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados